Clinical Trial: Treatment for Prader-Willi Syndrome

Research is uncovering new approaches to treating the hallmark symptoms of Prader-Willi syndrome. Later this year, Levo Therapeutics will initiate a phase 3 trial investigating LV-101 (intranasal carbetocin) in children ages 7-18 as a treatment for hyperphagia and behavior associated with Prader-Willi syndrome.

For more information and participating sites, please view the trial listing at: NCT03649477